Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced record financial results for the year ending 30 September 2025, with revenue, profit and employee numbers all reaching their highest levels to date.
Annual accounts released today show revenue increased to £1.1 billion, up £71.9 million (7%) on 2024. Pre-tax profit rose by 16% to £138.9 million, compared with £119.3 million in the previous year, while employee numbers have grown by 6% over the same period.
Almac reinvests all profits back into the company to support long-term growth. These latest results mark the fifth year of Almac Group’s £500 million+ global capital investment programme, first announced in November 2021. Since then, employee numbers have increased by more than 2,000, with over half of these new roles created in Northern Ireland.
The programme includes major investment across diagnostic and pharmaceutical development and manufacturing, clinical production and distribution, commercial manufacturing and packaging, global cold-chain infrastructure, and analytical services. It also supports significant campus improvements designed to enhance the working environment for employees.
Almac now employs more than 7,900 people worldwide and plays a vital role in helping develop, manufacture, test and distribute essential medicines for patients around the globe. During the financial year, the Group supported the development and ongoing commercial supply of hundreds of life-saving drugs across more than 20 therapeutic areas, including oncology, cardiology, immunology, gene therapy and neurology.
Alan Armstrong, Almac Group Chairman and CEO, said:
“These results reflect another successful year for Almac and demonstrate the resilience of our long-term growth strategy in a changing global environment.”
As a privately owned company, we are proud to reinvest our profits to support our global clients, drive innovation and expand our capabilities. None of this would be possible without the exceptional commitment of our people across the globe.”
-ends-
Notes to Editor:
- The employee percentage number rise in the financial accounts relates to the average employment figure for FY 2024/2025 vs 2023/2024. Employee numbers currently exceed 7,900 as of May 2026.
About Almac Group
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture and supply.
Almac is a privately owned organisation which has grown organically, now employing more than 7,900 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
The financial figures quoted in this announcement relate to the financial period 1 October 2024 to 30 September 2025.
To keep up to date with the latest news, follow us on X and LinkedIn or visit almacgroup.com.
